Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT‐11)
- 16 May 2003
- journal article
- case report
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 41 (1) , 78-80
- https://doi.org/10.1002/mpo.10300
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan*Medical and Pediatric Oncology, 2001
- Pretreatment prognostic factors for children with hepatoblastoma — results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1European Journal Of Cancer, 2000
- Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in ChildrenJournal of Clinical Oncology, 1999
- Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude miceInternational Journal of Cancer, 1997
- Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsBritish Journal of Cancer, 1996
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A siop pilot studyMedical and Pediatric Oncology, 1991
- Adriamycin and cisplatin for hepatoblastomaCancer, 1985